PMID- 34778312
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20211117
IS  - 2296-858X (Print)
IS  - 2296-858X (Electronic)
IS  - 2296-858X (Linking)
VI  - 8
DP  - 2021
TI  - Clinical Outcomes of Unrelated Umbilical Cord Blood Graft vs. Haploidentical 
      Donor Transplantation: Critical Issues for an Adequate Comparison.
PG  - 749810
LID - 10.3389/fmed.2021.749810 [doi]
LID - 749810
AB  - Unrelated umbilical cord blood (UCB) and haploidentical grafts have been used for 
      allogeneic hematopoietic stem and progenitor cell (HSPC) transplantation in 
      patients without a related or non-related human leukocyte antigen (HLA)-matched 
      donor. The less stringent HLA-matching requirement in both sources raises an 
      important possibility for patients in need of urgent transplantation to treat any 
      hematological disease. Selection of the best alternative donor is a difficult 
      task that will depend on donor criteria, center experience, patient disease 
      conditions, and risk, among others. Most comparisons available in scientific 
      publications between both graft sources are obtained from retrospective analysis 
      in wide time windows and a heterogeneous number of patients, types of disease, 
      disease stages, previous treatments, graft source, conditioning regimen, graft 
      vs. host disease (GVHD) approach, and evaluable endpoints. There is also an 
      evident impact of the economic traits since low-income countries must consider 
      less expensive treatments to satisfy the needs of the patients in the most 
      effective possible path. Therefore, haploidentical transplantation could be an 
      appealing option, even though it has not been completely established if any 
      chronic treatment derived from the procedure could become a higher cost. In 
      Colombia, there is a huge experience in UCB transplantation especially in units 
      of pediatric transplantation where benign indications are more common than in 
      adults. Due to the availability of a public UCB bank and HLA high-resolution 
      typing in Colombia, there is a wider inventory of cord blood donors. 
      Unfortunately, we do not have an unrelated bone marrow donor registry, so UCB is 
      an important source along with haploidentical transplantation to consider in 
      decision-making. This minireview focuses on comparing the main issues associated 
      with the use of both HSCP sources and provides tools for physicians who face the 
      difficult decision between these alternative donor sources.
CI  - Copyright (c) 2021 Vanegas, Nino-Quiroga, Chaparro, Camacho-Rodriguez, Estupinan 
      and Perdomo-Arciniegas.
FAU - Vanegas, Diana
AU  - Vanegas D
AD  - Cord Blood Bank, Instituto Distrital de Ciencia, Biotecnologia e Innovacion en 
      Salud, Bogota, Colombia.
FAU - Nino-Quiroga, Laura
AU  - Nino-Quiroga L
AD  - Cord Blood Bank, Instituto Distrital de Ciencia, Biotecnologia e Innovacion en 
      Salud, Bogota, Colombia.
FAU - Chaparro, Mauricio
AU  - Chaparro M
AD  - Unidad de Trasplante, Fundacion HOMI-Hospital de la Misericordia, Bogota, 
      Colombia.
FAU - Camacho-Rodriguez, Bernardo
AU  - Camacho-Rodriguez B
AD  - Cord Blood Bank, Instituto Distrital de Ciencia, Biotecnologia e Innovacion en 
      Salud, Bogota, Colombia.
FAU - Estupinan, Marcela
AU  - Estupinan M
AD  - Unidad de Trasplante, Fundacion HOMI-Hospital de la Misericordia, Bogota, 
      Colombia.
FAU - Perdomo-Arciniegas, Ana-Maria
AU  - Perdomo-Arciniegas AM
AD  - Cord Blood Bank, Instituto Distrital de Ciencia, Biotecnologia e Innovacion en 
      Salud, Bogota, Colombia.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20211028
PL  - Switzerland
TA  - Front Med (Lausanne)
JT  - Frontiers in medicine
JID - 101648047
PMC - PMC8581238
OTO - NOTNLM
OT  - HLA matching
OT  - clinical outcomes
OT  - cord blood
OT  - haploidentical
OT  - hematopoietic stem cell transplantation
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/11/16 06:00
MHDA- 2021/11/16 06:01
PMCR- 2021/10/28
CRDT- 2021/11/15 07:09
PHST- 2021/07/30 00:00 [received]
PHST- 2021/09/27 00:00 [accepted]
PHST- 2021/11/15 07:09 [entrez]
PHST- 2021/11/16 06:00 [pubmed]
PHST- 2021/11/16 06:01 [medline]
PHST- 2021/10/28 00:00 [pmc-release]
AID - 10.3389/fmed.2021.749810 [doi]
PST - epublish
SO  - Front Med (Lausanne). 2021 Oct 28;8:749810. doi: 10.3389/fmed.2021.749810. 
      eCollection 2021.